Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPA | Q15257 | 5/20 | 1.00 |
| ▸ | PPP2CA | P67775 | 4/20 | 1.00 |
| ▸ | PPP5C | P53041 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 11/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tautomycin SCHEMBL23008660 | 1.00 | PTPA (1.00) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL23008659 | 1.00 | PTPA (1.00) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL22965087 | 1.00 | PTPA (1.00) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL21298444 | 1.00 | PTPA (1.00) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL21298445 | 0.80 | PTPA (0.66) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL24974804 | 0.77 | PPP2CA (0.62) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL820638 | 0.58 | PPP2CA (0.76) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL15381937 | 0.57 | PPP2CA (0.57) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL15381933 | 0.57 | PPP2CA (0.88) | PTPAPPP2CAPPP5CPTPN1PPP1CC | |
| SCHEMBL15381938 | 0.56 | PPP2CA (0.90) | PTPAPPP2CAPPP5CPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564486-B2 | Devices and methods for treating an aneurysm | MERLIN MD PTE LTD. (SG) | 2026-03-03 | — | — | US | claimed |
| EP-4683654-A1 | SIRP VARIANTS AND USES THEREOF | Li, Wangzhi (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4673458-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2026-01-07 | — | — | EP | claimed |
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024213119-A1 | PH-SENSITIVE CD47-BINDING DOMAINS AND USES THEREOF | ADAPTOCUE, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024193635-A1 | SIRP VARIANTS AND USES THEREOF | LI, Wangzhi (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024180095-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2024-09-06 | — | — | WO | claimed |
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | Genosco Inc. (US) | 2024-08-20 | — | — | US | claimed |
| WO-2024085786-A1 | MEDIUM AND DEVICE FOR COLLECTING, STORING AND TRANSPORTING | Gra Olga Alekseevna (RU) | 2024-04-25 | — | — | WO | claimed |
| EP-4356731-A1 | MEDIUM AND DEVICE FOR COLLECTING, STORING AND TRANSPORTING BIOLOGICAL SAMPLES, AS WELL AS THEIR USE FOR THE STABILIZATION OF EXTRACELLULAR NUCLEIC ACIDS | Gra, Olga Alekseevna (RU) | 2024-04-24 | — | — | EP | claimed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0696730-B1 | Use of an inhibitor of serine/threonine protein phosphatases to induce premature chromosome condensation (PCC) | GOTOH EISUKE (JP) | 2002-11-06 | — | — | EP | claimed |
| JP-2002525268-A | — | — | 2002-08-13 | — | — | JP | claimed |
| US-20020061303-A1 | Inhibitors of angiogenesis and tumor growth for local and systemic administration | SINGH, SAIRA SAYED | 2002-05-23 | — | — | US | claimed |
| WO-2002028387-A1 | INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH FOR LOCAL AND SYSTEMIC ADMINISTRATION | ONCOPHARMACEUTICAL, INC. (US) | 2002-04-11 | — | — | WO | claimed |
| US-20020012703-A1 | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent | SINGH, SAIRA SAYED | 2002-01-31 | — | — | US | claimed |
| EP-1114144-A1 | TREATMENT OF ONCOLOGIC TUMORS WITH AN INJECTABLE FORMULATION OF A GOLGI APPARATUS DISTURBING AGENT | Oncopharmaceutical, Inc. (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015766-A1 | TREATMENT OF ONCOLOGIC TUMORS WITH AN INJECTABLE FORMULATION OF A GOLGI APPARATUS DISTURBING AGENT | ONCOPHARMACEUTICAL, INC. (US) | 2000-03-23 | — | — | WO | claimed |
| EP-0696730-A1 | Agents and a method of chromosome preparation using protein phosphatase inhibitors induced premature chromosome condensation (PCC) technique | Gotoh, Eisuke (JP) | 1996-02-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | ROCK2, ROCK1, MYLK3 | PTPA 762/4885PPP2CA 300/4885PPP5C 148/4885 |
| US-12564486-B2 | Devices and methods for treating an aneurysm | PDE1B, SMCHD1, PDE1C | PTPA 1892/4885PPP2CA 3375/4885PPP5C 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.